Home › Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension clinical trials recruiting in the U.S.
33 studies for Pulmonary Arterial Hypertension are recruiting participants at sites across the United States.
Cities with the most studies
- Aurora, CO7 studies
- Boston, MA7 studies
- Cincinnati, OH7 studies
- Kansas City, KS7 studies
- Durham, NC7 studies
- Nashville, TN7 studies
- Mountain View, CA7 studies
- Philadelphia, PA6 studies
- Seattle, WA5 studies
- New York City, NY5 studies
- Houston, TX4 studies
- Washington, DC4 studies
- Los Angeles, CA4 studies
- Louisville, KY4 studies
- Pittsburgh, PA4 studies
- Dallas, TX4 studies
- Minneapolis, MN3 studies
- Omaha, NE3 studies
- Jacksonville, FL3 studies
- Santa Barbara, CA3 studies
- Rochester, NY3 studies
- Scottsdale, AZ3 studies
- Richmond, VA3 studies
- Salt Lake City, UT3 studies
- Atlanta, GA3 studies
- Baltimore, MD3 studies
- San Francisco, CA3 studies
- St. Louis, MO3 studies
- Sacramento, CA3 studies
By state
- Arizona6 studies
- California12 studies
- Colorado7 studies
- Florida6 studies
- Georgia4 studies
- Kansas7 studies
- Kentucky4 studies
- Maryland5 studies
- Massachusetts7 studies
- Michigan3 studies
- Minnesota3 studies
- Missouri3 studies
- Nebraska3 studies
- New York6 studies
- North Carolina7 studies
- Ohio10 studies
- Oregon3 studies
- Pennsylvania8 studies
- South Carolina4 studies
- Tennessee8 studies
- Texas7 studies
- Utah3 studies
- Virginia3 studies
- Washington5 studies
Recently updated studies
A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Oct 2, 2026 · NCT07759804Spironolactone for Pulmonary Arterial Hypertension
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Oct 2, 2026 · NCT01712620A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07218029Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07318597Hormonal, Metabolic, and Signaling Interactions in PAH
RecruitingObservational studyHealthy volunteers welcome
Up to age 90 · All sexes · Updated Sep 25, 2026 · NCT01884051Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Sep 23, 2026 · NCT07613099A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 16, 2026 · NCT07481981A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07143448An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 2, 2026 · NCT07365332Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
RecruitingObservational studyHealthy volunteers welcome
Ages 0 to 20 · All sexes · Updated Aug 21, 2026 · NCT04278404The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
Recruiting
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT05464095Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 13, 2026 · NCT06992440A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Aug 10, 2026 · NCT07175038Xenon MRI Pulm Hypertension
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Aug 10, 2026 · NCT04991454A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Jul 31, 2026 · NCT06481852Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Jul 29, 2026 · NCT06274801A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
RecruitingPhase 1/2Healthy volunteers welcome
Ages 18 to 100 · All sexes · Updated Jul 21, 2026 · NCT06649110A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 45 · Women · Updated May 26, 2026 · NCT07312227Repurposing Valsartan May Protect Against Pulmonary Hypertension
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated May 4, 2026 · NCT06053580A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
RecruitingPhase 1
Ages 18 to 60 · All sexes · Updated Apr 23, 2026 · NCT06872112Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
RecruitingPhase 2
Ages 1 to 17 · All sexes · Updated Apr 20, 2026 · NCT05587712Mobile Health Intervention to Improve Exercise in Pediatric PH
Recruiting
Ages 10 to 21 · All sexes · Updated Mar 27, 2026 · NCT06549452Pulmonary Hypertension SOLAR
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 24, 2026 · NCT04778046129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Feb 24, 2026 · NCT06104228129 Xenon Imaging in Patients Treated With Sotatercept
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Feb 24, 2026 · NCT06351345From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.